Records containing: Ovarian Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-01-30Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
-
CLINICAL_TRIALS study record update · 2024-01-29Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA)
-
CLINICAL_TRIALS study record update · 2024-01-26STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands
-
CLINICAL_TRIALS study record update · 2024-01-26A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-01-25Adherence and Compliance to ERAS in Gynecological Surgery as Predictor of Postoperative Complications
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-01-25OPTimizing Treatment Focused Genetic Testing IN Cancer - OPT-IN
-
CLINICAL_TRIALS study record update · 2024-01-24Correlation Study of Symptom Clusters and Negative Emotions During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
-
CLINICAL_TRIALS study record update · 2024-01-24A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2024-01-23Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-01-22Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
-
CLINICAL_TRIALS study record update · 2024-01-22A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
-
CLINICAL_TRIALS study record update · 2024-01-19A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
-
CLINICAL_TRIALS study record update · 2024-01-19Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers - GeneBOPP
-
CLINICAL_TRIALS study record update · 2024-01-18An Open-label, Randomized, Controlled, Phase II/III Study of SHR-A1921 With or Without Carboplatin Verus Investigator's Choice of Platinum-based Doublet Chemotherapy in Patients With Recurrent Epithelial Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-01-17Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
-
CLINICAL_TRIALS study record update · 2024-01-17A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
-
CLINICAL_TRIALS study record update · 2024-01-16SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
-
CLINICAL_TRIALS study record update · 2024-01-12A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
-
CLINICAL_TRIALS study record update · 2024-01-11Follow-Up Study of Women Evaluated and Treated for Infertility
-
CLINICAL_TRIALS study record update · 2024-01-05The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies
-
CLINICAL_TRIALS study record update · 2024-01-05Phase Ib/II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody (AK112) Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-01-05A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
-
CLINICAL_TRIALS study record update · 2024-01-03Clinical Study of Fluzopalil Combined With Apatinib for Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-12-29A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
-
CLINICAL_TRIALS study record update · 2023-12-28Evaluation of Prognostic and Predictive Values of Bespoke Circulating Tumor DNA Assay for Recurrent and Response Monitoring in Patients With Advanced Epithelial Ovarian Cancer